0001628280-26-030549
SEC filingRevenue accelerated 84% to $60.1M driven by higher IMCIVREE volumes domestically and internationally, while gross margin held resilient at 88.1% despite scaling costs, but operating losses widened to -$52.4M from intensified investments outpacing topline gains.
Gross profitability remained resilient with gross profit up 82% to $53.0 million and a steady 88.1% gross margin. Management attributes cost of sales dynamics to revenue-linked factors, including additional royalties and higher product costs from increased volumes, alongside expectations of further cost of sales elevation in 2026 from selling capitalized IMCIVREE commercial inventory. Amortization expense embedded in cost of sales underscores the scaling production investments now flowing through as revenue grows, maintaining margin strength despite these pressures.